WuXi building twelfth plant as biologics contracts ramp up

Dan Stanton, Editorial director

November 22, 2018

2 Min Read
WuXi building twelfth plant as biologics contracts ramp up
China's WuXi Biologics is building another plant to deal with growing biomanufacturing services demand. Image: iStock/liulolo

With a portfolio approaching 200 products, CDMO WuXi Biologics has begun constructing a 1.6 million square-foot facility in Shanghai, China.

Contract development and manufacturing organization (CDMO) WuXi Biologics is building what it calls a ‘Biologics Innovation Center’ in Fengxian, Shanghai. The 1.6 million square-foot facility will include biologics discovery and development laboratories, as well as GMP manufacturing, CEO Chris Chen told BioProcessing Insider.

He added the labs will open in 2019, while the GMP plant will open its doors in 2021, though for now the planned “significant” capacity has not been disclosed.

china-economy-liulolo-300x200.jpg

China’s WuXi Biologics is building another plant to deal with growing biomanufacturing services demand. Image: iStock/liulolo

WuXi has been rapidly expanding over the past few years, and this latest project will become the twelfth biomanufacturing plant in the firm’s network. Earlier this year, the CDMO announced it was constructing two facilities in Shijiazhuang, China with a total of 52,500 L of single-use capacity, set to become its sixth and seventh Chinese facility.

The firm has also begun taking steps outside its native China, announcing facilities in Ireland, Singapore, and Massachusetts (US) over the past seven months.

According to Chen, the rapid expansion is required to deal with the growing demand for biologics manufacturing and services the firm is seeing. “We have a portfolio of 187 biologics that need manufacturing, and the number of projects is still growing.”

Once complete, the Fengxian site will hire more than 3,000 scientists, most of which will be sourced from China.

WuXi Biologic’s Global Network

DS Capacity

MFG1

5,000 L fed-batch/perfusion

2012

Wuxi, China

Commercial

MFG2

28,000 L fed-batch

2,000 L perfusion

2017

Wuxi, China

Commercial

MFG3

5,200 L fed-batch

2018

Shanghai, China

Clinical

MFG4

10,000 L fed-batch

2019

Wuxi, China

Clinical/Commercial

MFG5

60,000 L fed-batch

2020

Wuxi, China

Commercial

MFG6

6 x 1,000 L perfusion

2021

Mullagharlin, Ireland

Commercial

MFG7

48,000 L fed-batch

2021

Mullagharlin, Ireland

Commercial

MFG8

48,000 L fed-batch

2021

Shijiazhuang, China

Commercial

MFG9

4,500 L fed-batch/perfusion

2022

Shijiazhuang, China

Clinical/Commercial

MFG10

4,500 L fed-batch/perfusion

2022

Singapore

Clinical/Commercial

MFG11

4,500 L fed-batch/perfusion

2020

Massachusetts, US

Clinical/Commercial

MFG12

 ‘Biologics Innovation Center,’ undisclosed capacity

2021

Fengxian, Shanghai, China

Clinical/Commercial

About the Author

Dan Stanton

Editorial director

Journalist covering the international biopharmaceutical manufacturing and processing industries.
Founder and editor of Bioprocess Insider, a daily news offshoot of publication Bioprocess International, with expertise in the pharmaceutical and healthcare sectors, in particular, the following niches: CROs, CDMOs, M&A, IPOs, biotech, bioprocessing methods and equipment, drug delivery, regulatory affairs and business development.

From London, UK originally but currently based in Montpellier, France through a round-a-bout adventure that has seen me live and work in Leeds (UK), London, New Zealand, and China.

You May Also Like